Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.
An in vitro antimicrobial and safety study of *Lactobacillus reuteri* DPC16 for validation of probiotic concept

*A thesis presented in partial fulfilment of the requirements for the degree of Master of Technology in Biotechnology at Massey University, Auckland, New Zealand.*

LEI BIAN
(2008)

**Supervisors:**

Dr. Abdul Molan
Institute of Food Nutrition and Human Health
Massey University
Palmerston North

Professor Ian S. Maddox
School of Engineering and Advanced Technology
Massey University
Albany, Auckland

Dr. Quan Shu
Bioactive Research New Zealand
Mt. Albert, Auckland
Abstract

Based on previous studies of the novel *Lactobacillus reuteri* DPC16 strain, an *in vitro* investigation on the supernatant antimicrobial activity and the culture safety against normal gastrointestinal microflora and gastric mucus was done in this thesis.

DPC16 cell-free supernatants (fresh and freeze-dried, designated as MRSc and FZMRSsc) from anaerobic incubations in pre-reduced MRS broth, have shown significant inhibitory effects against selected pathogens, including *Salmonella Typhimurium*, *E. coli* O157:H7, *Staphylococcus aureus*, and *Listeria monocytogenes*. These effects were mainly due to the acid production during incubation as evidenced by the negation of such activity from their pH-neutral counterparts, and this acidic effect was shown to reduce the pathogen growth rate and decrease the total number of pathogen cells.

By incubation of concentrated (11 g/L) resting cells in glycerol-supplemented MRS broth, another DPC16 cell-free supernatant (designated as MRSg) has shown very strong antimicrobial effect against all target pathogens. As indicated by a kinetic profile, this activity developed in a sigmoidal fashion as incubation proceeded, reaching to maximum activity after 6-8h and maintained at the same level thereafter. Further study has shown that the antimicrobial activity of this supernatant was pH-independent, effective across a pH range of 4.6 to 6.5, and acted on both Gram-negative and Gram-positive pathogens. Using the minimum effective dose, a time course investigation has provided evidence that this supernatant affected the growth of the target pathogens by elongating the lag phase and lowering the total cell number at the end of the incubation. Lastly, it was found that the strong antimicrobial effect of MRSg was bactericidal at high concentrations and bacteriostatic at low concentrations. However, it also found that the viability of DPC16 cells also decreased as incubation prolonged, which suggests that this glycerol-derived supernatant had a lethal effect to its own cells. Nevertheless, this lethal effect was exerted to a much lesser extent compared with that to the pathogens.

The last DPC16 cell-free supernatant was designated as SGF, which was produced from secondary fermentation of the same resting cells in glycerol-water. SGF did not show a
significant antimicrobial activity, which suggests that this specific strain is not capable of utilising glycerol in the absence of fermentable carbohydrates.

The antimicrobial activity found in MRSg matched with previously published characteristics of reuterin, which is a unique antimicrobial substance synthesised by *L. reuteri* when incubated with glycerol. Therefore, a study on the production kinetics of reuterin by DPC16 was carried out. Supernatants of both MRSg and SGF were studied. Results showed that glycerol utilisation occurred in both MRSg and SGF, whereas the bioconversion of glycerol into reuterin was different. In MRSg, glycerol was constantly utilised by DPC16 resting cells, and by the end of an 18h incubation 85.8 mM of glycerol was utilised, where 72.8% was transformed into reuterin. The formation of reuterin initiated with an inclining production and reached the maximum rate of 10.9 mM/h after 6h of incubation, with the total production of 64 mM of reuterin at the end of the 18h incubation. This reuterin production in MRSg followed a similar pattern to that of its antimicrobial activity, which suggests a certain correlation between reuterin formation and the increase of antimicrobial activity in MRSg. Therefore, the major antimicrobial component in MRSg that accounted for its potent antimicrobial activity was very much likely to be reuterin. In SGF, however, detectable reuterin was negligible even though some glycerol may have been absorbed into the highly concentrated DPC16 resting cells. This has responded to the antimicrobial activity assay in that due to the lack of essential carbohydrate nutrient for normal cell metabolism, there was no glycerol utilisation and hence no reuterin synthesis.

Having studied the antimicrobial activity of *L. reuteri* DPC16 and the production of antimicrobial-competent reuterin, two safety issues (the impact on growth on other normal commensal probiotics and mucin degradation activity) of this strain were assessed to further evaluate its probiotic potential. By using similar *in vitro* assays as in the antimicrobial test, the same set of DPC16 supernatants have demonstrated no adverse effect on the growth of either *Lactobacillus acidophilus*, *Lactobacillus plantarum*, *Pediococcus acidilactici*, or *Bifidobacterium lactis* DR10. No stimulatory effect was found either. By incorporating purified porcine gastric mucin into classic mucin-degradation assays in both liquid and agar media, DPC16 has not exhibited the same mucinolytic activity as that of the faecal flora cultures. Thus, it can be concluded that *L. reuteri* DPC16 is as safe to the host as normal commensal microflora.
Acknowledgement

First of all, I wish to take this opportunity to express my most sincere gratitude to all my supervisors who have helped and supported me with the completion of this thesis. Without their advice and encouragement, this thesis would not have been possible.

In particular, I would like to thank my chief supervisor, Dr. Abdul Molan, for his professional guidance and continuous encouragement throughout the course of this thesis.

Equally, I am sincerely grateful to my co-supervisor, Professor Ian Maddox, for his long-term supervision, concerns and encouragements since 2005.

I will also thank Dr. Quan Shu, my third supervisor, for his leadership and for offering me this opportunity to study and research.

I wish to express my sincere gratitude to Bioactive Research New Zealand Ltd., who not only funded this research, but also provided all the stock bacteria strains and extensive laboratory supports.

I will also acknowledge my gratitude to Crop and Food Research at Mt. Albert Research Centre, Auckland, for their generous and kind support with lab facility. Specifically, I would thank Graham Fletcher, Graeme Summers, Douglas Rosendale, Muftikhar Ahmed, and the former laboratory manager Mr. Joseph Yoseph. Without their helps and kind supports, this thesis would not have been completed to the current extent. In addition, I would acknowledge my special thanks to Douglas Rosendale for not only advising me on my experiments but also proofreading the thesis.

I am also grateful to the colleagues and research fellows working at Bioactive Research, including the technical and production manager, Robert Peng, the PhD candidate Sabrina Tian and Sean Chen. The discussion forum we established has equipped me with knowledge and ideas in scientific discovery.

Finally, I would like to thank my family, my wife Sunny R. Han, my son David Bian, and my parents in China. Their endless love, support and encouragement were the fuel driving me towards the accomplishment of this research.
### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>3-HPA</td>
<td>3-hydroxypropionaldehyde</td>
</tr>
<tr>
<td>BblL</td>
<td><em>B. lactis</em> DR10 culture</td>
</tr>
<tr>
<td>BHI</td>
<td>Brain heart infusion broth</td>
</tr>
<tr>
<td>EMP</td>
<td>Embden-Meyerhof pathway</td>
</tr>
<tr>
<td>FF</td>
<td>Faecal flora culture</td>
</tr>
<tr>
<td>FHEF</td>
<td>Facultative hetero-fermentation</td>
</tr>
<tr>
<td>FZMRSc</td>
<td>Aqueous solution of freeze-dried MRSc</td>
</tr>
<tr>
<td>GI</td>
<td>Gastrointestinal</td>
</tr>
<tr>
<td>HFF</td>
<td>Heat-killed faecal flora culture</td>
</tr>
<tr>
<td>LAB</td>
<td>Lactic acid bacteria</td>
</tr>
<tr>
<td>LR</td>
<td><em>L. reuteri</em> DPC16 culture in pre-reduced MRS</td>
</tr>
<tr>
<td>LRg</td>
<td><em>L. reuteri</em> DPC16 glycerol fermentation</td>
</tr>
<tr>
<td>MAP</td>
<td>Modified atmosphere packaging</td>
</tr>
<tr>
<td>MIC</td>
<td>Minimum inhibition concentration</td>
</tr>
<tr>
<td>MRSc</td>
<td>DPC16 supernatant from incubation in MRS</td>
</tr>
<tr>
<td>MRSg</td>
<td>DPC16 supernatant derived from glycerol-MRS incubation</td>
</tr>
<tr>
<td>NAD+</td>
<td>Nicotinamide adenine dinucleotide</td>
</tr>
<tr>
<td>NADH</td>
<td>Reduced form of NAD+</td>
</tr>
<tr>
<td>OD</td>
<td>Optical density</td>
</tr>
<tr>
<td>OHEF</td>
<td>Obligate hetero-fermentation</td>
</tr>
<tr>
<td>OHOF</td>
<td>Obligate homo-fermentation</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate buffered saline</td>
</tr>
<tr>
<td>PKP</td>
<td>Phosphoketolase pathway</td>
</tr>
<tr>
<td>PGM</td>
<td>Porcine gastric mucin</td>
</tr>
<tr>
<td>RPM</td>
<td>Revolution per minute</td>
</tr>
<tr>
<td>SCFA</td>
<td>Short chain fatty acids</td>
</tr>
<tr>
<td>SEM</td>
<td>Standard error of the mean</td>
</tr>
<tr>
<td>SGF</td>
<td>Sole glycerol ferment (DPC16 supernatant from glycerol-water fermentation)</td>
</tr>
</tbody>
</table>
# Table of Content

Abstract ................................................................................................................................. I

Acknowledgement ........................................................................................................... III

Abbreviations .................................................................................................................. IV

Table of Content ............................................................................................................. V

List of Figures ................................................................................................................... IX

List of Tables .................................................................................................................... XI

Chapter 1  General Introduction ..................................................................................... 1

Chapter 2  Literature Review .......................................................................................... 3

2.1  Probiotics .................................................................................................................. 3
    2.1.1  Common physiology of probiotics .............................................................. 4
    2.1.2  Applications of probiotics .......................................................................... 5

2.2  Function of probiotics ............................................................................................. 6
    2.2.1  Overview of probiotic functions .................................................................. 6
    2.2.2  Antimicrobial activities .............................................................................. 6

2.3  Safety of Probiotics ................................................................................................ 9
    2.3.1  Clinical infections ...................................................................................... 9
    2.3.2  Safety Guidelines for probiotics ............................................................... 10

2.4  *Lactobacillus reuteri* ............................................................................................ 11
    2.4.1  Historical background .............................................................................. 11
    2.4.2  Morphology ................................................................................................ 11
    2.4.3  Ecology ...................................................................................................... 11
    2.4.4  Biochemistry ............................................................................................. 12
    2.4.5  Antimicrobial activity of *Lactobacillus reuteri* ........................................ 15
        2.4.5.1  Reuterin ............................................................................................ 15
        2.4.5.2  Reutericin ......................................................................................... 17
        2.4.5.3  Reutericyclin .................................................................................. 17
    2.4.6  Other functions of *Lactobacillus reuteri* .................................................. 18
Table of Content

2.4.7 Production of reuterin ................................................................. 18
2.4.8 Safety of \textit{Lactobacillus reuteri} ............................................ 21
2.4.9 Applications of \textit{Lactobacillus reuteri} ................................. 22
2.5 \textit{Lactobacillus reuteri} DPC16 .................................................... 23
   2.5.1 Origin and identification ....................................................... 23
   2.5.2 Previous studies on \textit{Lactobacillus reuteri} DPC16 ............... 23
2.6 Hypotheses ................................................................................... 24

Chapter 3 \textbf{Antimicrobial activity of \textit{Lactobacillus reuteri} DPC16 cell-free supernatants against selected food borne pathogens} ........................ 26

3.1 Introduction .................................................................................. 26
3.2 Materials and Methods ................................................................. 28
   3.2.1 Growth of pathogen cultures ................................................... 28
   3.2.2 Preparation of DPC16 cell-free supernatants ............................ 29
   3.2.3 Primary antimicrobial assay of DPC16 supernatants ................ 31
   3.2.4 Dose response test ................................................................. 31
   3.2.5 A time course investigating the antimicrobial activity of DPC16 supernatants ..................................................... 32
   3.2.6 An antimicrobial efficiency test using MRSg ......................... 32
   3.2.7 Viability of DPC16 resting cells in glycerol-fermenting cultures .... 32
   3.2.8 Statistical analysis ................................................................. 33
3.3 Results ........................................................................................... 34
   3.3.1 The pH values of DPC16 cell-free supernatants ....................... 34
   3.3.2 Primary antimicrobial assay against selected pathogens .......... 34
   3.3.3 Dose response test ................................................................. 39
   3.3.4 A time course investigation of DPC16 antimicrobial activity on pathogen growth ......................................................... 43
   3.3.5 An antimicrobial efficiency test on MRSg ............................... 48
   3.3.6 Viability of DPC16 resting cells in glycerol-fermenting cultures .... 49
3.4 Discussion ...................................................................................... 51
## Table of Content

### Chapter 4  Kinetics of *Lactobacillus reuteri* DPC16 growth and *in situ* reuterin production in a two-step fermentation process ................................. 57

4.1 Introduction........................................................................................................ 57  
4.2 Materials and Methods....................................................................................... 59  
4.2.1 Culture preparation.................................................................................. 59  
4.2.2 Growth curve of *L. reuteri* DPC16 in pre-reduced MRS broth .............. 59  
4.2.3 Measurement of DPC16 dry matter by freeze-drying............................. 59  
4.2.4 Colorimetric determination of glycerol and reuterin .............................. 60  
4.2.4.1 Glycerol............................................................................................ 60  
4.2.4.2 Reuterin............................................................................................ 61  
4.2.5 Relationship between reuterin and the antimicrobial activity in DPC16 supernatants from glycerol fermentation ................................................ 62  
4.3 Results................................................................................................................ 62  
4.3.1 Viable cell enumeration and pH measurement of DPC16 culture .......... 62  
4.3.2 Growth of *L. reuteri* DPC16 in MRS under anaerobic condition ........... 63  
4.3.3 Bioconversion of glycerol and yield of reuterin from biomass............... 65  
4.3.4 Reuterin and antimicrobial activity ......................................................... 66  
4.4 Discussion.......................................................................................................... 68

### Chapter 5  Evaluating the impacts of *Lactobacillus reuteri* DPC16 on mucin degradation and on the growth of other probiotics, *in vitro*..................... 73

5.1 Introduction........................................................................................................ 73  
5.2 Materials and Methods....................................................................................... 76  
5.2.1 The effect of DPC16 supernatants on growth of the selected probiotic strains .......................................................... 76  
5.2.2 Mucin degradation .................................................................................. 77  
5.2.2.1 Mucin purification............................................................................ 77  
5.2.2.2 Basal medium for anaerobic cultures............................................ 77  
5.2.2.3 Bacterial cultures............................................................................. 78  
5.2.2.4 Mucin degradation assays .............................................................. 79  
5.3 Results................................................................................................................ 80  
5.3.1 The effects of DPC16 supernatants on growth of the selected probiotic strains .......................................................... 80  
5.3.2 Degradation of mucin in liquid media ..................................................... 83
Table of Content

5.3.3 Degradation of mucin on agarose plate ................................................... 84
5.4 Discussion ........................................................................................................ 85

Chapter 6 General discussions and conclusion ................................................. 88

References ............................................................................................................ 92

Appendices .......................................................................................................... 110

Appendix 1 Ingredients of cultural growth media .............................................. 110
Appendix 2 Raw data and statistics ..................................................................... 111
Appendix 3 Standard curves for colorimetric assays of glycerol and reuterin .... 114
List of Figures

Figure 2.1  Heterofermentation of glucose by *Lactobacillus reuteri* in phosphoketolase pathway ................................................................. 13

Figure 2.2  *Lactobacillus reuteri* production of 3-HPA during glycerol fermentation 14

Figure 2.3  Chemical dehydration of 3-HPA (reuterin) to acrolein, followed by further oxidation to 1,3-propanediol ........................................... 20

Figure 3.1  The pH values of MRSg and SGF measured during secondary fermentation with glycerol ............................................................... 34

Figure 3.2  Primary antimicrobial tests of MRSc and FZMRSc, and their pH adjusted counterparts ............................................................. 35

Figure 3.3  Primary antimicrobial test of MRSg harvested during a secondary fermentation ................................................................................. 38

Figure 3.4  Post-treatment viability test of pathogens treated with MRSg harvested from selected time points during secondary fermentation with glycerol. 38

Figure 3.5  Primary antimicrobial test of SGF harvested during secondary fermentation ....................................................................................... 38

Figure 3.6  Dose response of original MRSc against pathogens............................... 40

Figure 3.7  Dose response of original FZMRSc against pathogens ......................... 41

Figure 3.8  Dose response of original MRSg-8h against pathogens ....................... 42

Figure 3.9  Dose response of SGF-2h against pathogens ......................................... 42

Figure 3.10  A time course of original MRSc treatment, in minimum effective dose, against selected pathogens .................................................... 44

Figure 3.11  A time course of original FZMRS treatment, in minimum effective dose, against selected pathogens ....................................................... 45

Figure 3.12  A time course of MRSg treatment, in minimum effective dose, against selected pathogens ............................................................... 46

Figure 3.13  A time course of undiluted SGF treatment against *S. Typhimurium* and *S. aureus* ........................................................................... 46

Figure 3.14  A time trend of cells viability of *L. reuteri* DPC16 resting cells in batch culture incubation of glycerol supplemented media .................. 50
List of Figures

Figure 4.1  Correlation curve of OD_{620} and the numbers of viable cells in a DPC16 culture incubated in MRS for 20h ............................................................ 62

Figure 4.2  Growth curve of DPC16 in pre-reduced MRS during anaerobic incubation at 37°C ...................................................................................................... 63

Figure 4.3  Correlation curve of OD_{620} and CDW of DPC16 culture incubated in MRS for 20h. ..................................................................................................... 64

Figure 4.4  Time course of *L. reuteri* DPC16 resting cells bioconversion of glycerol to reuterin in MRSg and SGF .............................................................. 65

Figure 4.5  Production rate of reuterin during incubation of DPC16 in glycerol-MSR broth under standardised conditions. ....................................................... 66

Figure 4.6  Antimicrobial activity of MRSg, expressed as concentration of reuterin, exhibited during the secondary fermentation of glycerol in MRS broth. 67

Figure 5.1  Growth curves of probiotic strains in MRS during anaerobic incubation at 37°C ......................................................................................................... 80

Figure 5.2  Effects of MRSc, FZMRSc and their pH-adjusted counterparts on the growth of selected probiotic cultures .......................................................... 81

Figure 5.3  Effects of MRSg, SGF and pH-adjusted MRSg on the growth of selected probiotic cultures .................................................................................. 82

Figure 5.4  A time course of probiotic strains treated with and without MRSg-8h or its pH-adjusted counterpart ........................................................................... 82

Figure 5.5  Growth of potential probiotic cultures and faecal flora cultures in basal medium supplemented with designated carbohydrate sources ........... 83

Figure 5.6  Degradation of mucin on agarose plate supplemented with PGM only and PGM with glucose ................................................................................. 84
List of Tables

Table 3.1  Summary of DPC16 cell-free supernatants derived from various cultural media ..........................................................................................................................30

Table 3.2  Antimicrobial activity of the MRSg (non-pH-adjusted), from selected time points during incubation, against target pathogens .................................................................36

Table 3.3  The lowest effective dose of each selected original supernatant (non-pH adjusted) against target pathogens. .................................................................................43

Table 3.4  A statistical analysis of pathogen growth rate with and without treatments from the designated DPC16 supernatants ..............................................................................47

Table 3.5  A statistical analysis comparing the number of total pathogen cells at the of the incubation, between pathogens treated with respective DPC16 supernatants and the untreated controls .................................................................48

Table 3.6  Sensitivity of pathogens to MRSg-8h treatment .................................................................................49

Table 5.1  Ingredients of basal medium for mucin degradation assay .................................................................77

Table 5.2  The final pH value of cultures incubated in various media comparing with their original culture which indicate the starting pH values ...............................................84